Abstract
MARK3 (microtubule affinity regulating kinase 3) is a serine/threonine protein kinase. The protein kinases have a regulatory role in cell biology, involved in a variety of cellular processes such as apoptosis, cell cycle, cytoskeletal rearrangement, immune response, nervous system function, and transcription. Deregulation of these protein kinases triggers a variety of diseases such as cancer, diabetes, cardiovascular and nervous system disorders, which highlights this family of proteins as druggable targets. However, the development of competitive inhibitors to protein kinases is a challenging task due to the high level of similarity between members of this family, ranging from 50 to 85 % of sequence identity. The structure-based techniques were performed to design novel MARK3 inhibitors. Structure-based virtual screening experiments were performed selecting 20 compounds whose activity profiles were predicted using PASS and DEREK softwares. In addition, the top docking solutions were evaluated by molecular dynamics simulations.
Keywords: Cancer, MARK3, structure-based virtual screening.
Current Bioactive Compounds
Title:Structure-Based Drug Design of Novel MARK-3 Inhibitors in Cancer
Volume: 10 Issue: 2
Author(s): Josiana G. de Araujo Volpini, Ricardo P. Rodrigues, Leonardo B. Federico and Carlos H.T. de Paula da Silva
Affiliation:
Keywords: Cancer, MARK3, structure-based virtual screening.
Abstract: MARK3 (microtubule affinity regulating kinase 3) is a serine/threonine protein kinase. The protein kinases have a regulatory role in cell biology, involved in a variety of cellular processes such as apoptosis, cell cycle, cytoskeletal rearrangement, immune response, nervous system function, and transcription. Deregulation of these protein kinases triggers a variety of diseases such as cancer, diabetes, cardiovascular and nervous system disorders, which highlights this family of proteins as druggable targets. However, the development of competitive inhibitors to protein kinases is a challenging task due to the high level of similarity between members of this family, ranging from 50 to 85 % of sequence identity. The structure-based techniques were performed to design novel MARK3 inhibitors. Structure-based virtual screening experiments were performed selecting 20 compounds whose activity profiles were predicted using PASS and DEREK softwares. In addition, the top docking solutions were evaluated by molecular dynamics simulations.
Export Options
About this article
Cite this article as:
de Araujo Volpini Josiana G., P. Rodrigues Ricardo, B. Federico Leonardo and de Paula da Silva Carlos H.T., Structure-Based Drug Design of Novel MARK-3 Inhibitors in Cancer, Current Bioactive Compounds 2014; 10 (2) . https://dx.doi.org/10.2174/157340721002141001103308
DOI https://dx.doi.org/10.2174/157340721002141001103308 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting HOTAIR induces mitochondria related apoptosis and inhibits tumor growth in head and neck squamous cell carcinoma in vitro and in vivo.
Current Molecular Medicine The Return of the INGs, Histone Mark Sensors and Phospholipid Signaling Effectors
Current Drug Targets Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics
Current Drug Targets Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Employing Genetic Markers to Improve Diagnosis of Thyroid Tumor Fine Needle Biopsy
Current Genomics Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy in Plastic and Reconstructive Surgery
Current Gene Therapy New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging Unfoldomics of Human Genetic Diseases: Illustrative Examples of Ordered and Intrinsically Disordered Members of the Human Diseasome
Protein & Peptide Letters Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Iterative Image Reconstruction Algorithms for CT Metal Artifact Reduction: A Review
Recent Patents on Medical Imaging Selenium Derivatives as Cancer Preventive Agents
Current Medicinal Chemistry - Anti-Cancer Agents Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics A Comprehensive Review on Nanotechnology-Based Innovations in Topical Drug Delivery for the Treatment of Skin Cancer
Current Pharmaceutical Design Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Magnetic Resonance Imaging of Uncommon Hepatic Mesenchymal Tumours: Haemangioendothelioma and Angiosarcoma
Current Medical Imaging Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets